Clinical
RSSArticles
-
Clinical Briefs
Modifying the Home Environment to Prevent Falls
-
Secukinumab Injection (Cosentyx™)
A recombinant, fully humanized monoclonal antibody to interleukin-17 has been approved for the treatment of moderate-to-severe plaque psoriasis. Secukinumab is marketed by Novartis as Cosentyx.
-
B-type Natriuretic Peptides (BNP) Values Improve CVD Risk Prediction
Elevated BNP values in a large cohort of women with numerous CV events modestly improved measures of CVD risk prediction.
-
Does a Link Exist Between OSA and CAD?
Obstructive sleep apnea is associated with coronary artery calcification in non-obese individuals, but the effect is largely attenuated by body mass index.
-
Statins After an MI: Does it Happen?
Following hospital discharge for a heart attack, the majority of Medicare patients do not get recommended high-intensity statin therapy.
-
Farewell and Welcome
Dr. Robert Coleman, a member of the editorial board of OB/GYN Clinical Alert since 2004, has been elected as the next President of the Society of Gynecologic Oncologists.
-
Postoperative Delirium in Older Adults
The elderly operative patient has very different and specific needs compared to a younger woman. In addition to a higher risk of medical comorbidities, elderly women are affected by cognitive impairment, depression, gait, and balance disturbances.
-
NIPT and Invasive Procedures
A single prenatal testing center with a large volume of patients has experienced a dramatic drop in the rate of chorionic villus sampling and amniocentesis after the introduction of noninvasive prenatal testing.
-
Hormonal Contraception and Glioma: Is There Reason for Concern?
A large case-control study using the Danish National database found a slight increase in the risk of glioma in ever-users of hormonal contraception, which increased with duration of use. Users of progestin-only methods were at higher risk. However, these findings should not influence clinical practice or perception of contraceptive safety.
-
Finding New Clinical Activity in Endometrial Cancer from Optimizing Molecular Pathways
Everolimus, combined with letrozole, produced unexpected clinical activity in a cohort of previously treated recurrent endometrial cancer patients.